Grifols (NASDAQ:GRFS) Rating Increased to Buy at Wall Street Zen

Key Points

• Wall Street Zen upgraded Grifols from “hold” to “buy,” although the broader analyst consensus remains “Reduce,” with two holds and one sell rating and an average price target of $10.
• Grifols shares opened at $7.31, near their 52-week low of $6.96, with a $4.98 billion market capitalization and a price-to-earnings ratio of 38.47.
• Several institutional investors increased their Grifols holdings, including Tidal Investments, Hennion & Walsh Asset Management, Versant Capital Management and EverSource Wealth Advisors.

Grifols (NASDAQ:GRFS - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued on Saturday, Wall Street Zen reports.

Several other brokerages have also commented on GRFS. Zacks Research upgraded shares of Grifols from a "strong sell" rating to a "hold" rating in a research note on Tuesday, July 7th. Weiss Ratings upgraded shares of Grifols from a "sell (d)" rating to a "sell (d+)" rating in a research report on Monday, August 17th. Two equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Reduce" and an average target price of $10.00.

Grifols Price Performance

Shares of NASDAQ GRFS opened at $7.31 on Friday. The company has a debt-to-equity ratio of 1.10, a quick ratio of 0.81 and a current ratio of 2.37. Grifols has a fifty-two week low of $6.96 and a fifty-two week high of $10.23. The firm has a market capitalization of $4.98 billion, a PE ratio of 38.47, a price-to-earnings-growth ratio of 0.27 and a beta of 0.67. The stock's 50-day simple moving average is $7.75 and its 200-day simple moving average is $7.83.

Institutional Trading of Grifols

Several institutional investors and hedge funds have recently bought and sold shares of the business. Tidal Investments LLC increased its stake in Grifols by 9.8% in the second quarter. Tidal Investments LLC now owns 1,233,082 shares of the biotechnology company's stock valued at $8,730,000 after purchasing an additional 109,612 shares during the period. Compass Wealth Management LLC purchased a new position in shares of Grifols during the second quarter worth about $108,000. Hennion & Walsh Asset Management Inc. increased its position in Grifols by 13.8% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 592,173 shares of the biotechnology company's stock valued at $4,193,000 after acquiring an additional 72,037 shares during the period. Versant Capital Management Inc increased its position in Grifols by 36.0% in the 2nd quarter. Versant Capital Management Inc now owns 6,958 shares of the biotechnology company's stock valued at $49,000 after acquiring an additional 1,842 shares during the period. Finally, EverSource Wealth Advisors LLC raised its stake in Grifols by 71.6% during the 1st quarter. EverSource Wealth Advisors LLC now owns 14,685 shares of the biotechnology company's stock valued at $118,000 after acquiring an additional 6,127 shares during the last quarter.

Grifols Company Profile

Grifols SA is a global healthcare company headquartered in Barcelona, Spain, and listed on Nasdaq under the symbol GRFS. Founded in 1909, the company specializes in plasma-derived medicines and other products used to treat chronic and rare diseases.

Its biopharma business develops and manufactures therapies derived from human plasma, including immunoglobulins, albumin, coagulation factors and alpha-1 antitrypsin. These products support patients with immune deficiencies, bleeding disorders, liver conditions and certain respiratory diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.